Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-13 |
2024-09 |
0.36 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
-0.15 |
0.01 |
0.16 |
106.67% |
2024-05-09 |
2024-03 |
-0.17 |
-0.08 |
0.09 |
52.94% |
2024-05-09 |
2024-03 |
-0.17 |
N/A |
N/A |
N/A |
2024-03-25 |
2023-12 |
-0.17 |
N/A |
N/A |
N/A |
2024-03-25 |
2023-12 |
-0.17 |
-0.07 |
0.1 |
58.82% |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-04-30 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-03-23 |
Stifel |
Upgrade |
|
Buy |
2023-02-07 |
SVB Leerink |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2018-10-15 |
BIOCON SA |
Beneficial Owner of more than 10% of a Class of Security |
2.32M |
Stock Award(Grant) |
2021-10-05 |
CONNELLY STEPHEN |
Officer and Director |
993.00K |
Sale |
2024-09-25 |
KEYES JASON A |
Chief Financial Officer |
0.00 |
Sale |
2023-12-07 |
ROTHMAN JOEL |
Officer |
58.15K |
Stock Award(Grant) |
2024-09-15 |
TOM PENNY |
Officer |
10.05K |
Sale |
2023-12-07 |
ZEDELMAYER CHRISTINE |
Chief Operating Officer |
135.25K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Decheng Capital Management III (Cayman), LLC |
4.45M |
3.34M |
12.87% |
2023-06-29 |
JP Morgan Chase & Company |
1.19M |
893.49K |
3.45% |
2023-06-29 |
Franklin Resources, Inc. |
895.00K |
671.25K |
2.59% |
2023-06-29 |
Vanguard Group Inc |
836.93K |
627.70K |
2.42% |
2023-06-29 |
Cota Capital Management, Llc |
562.28K |
421.71K |
1.63% |
2023-06-29 |
Tang Capital Management, LLC |
400.00K |
300.00K |
1.16% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
570.84K |
428.13K |
1.65% |
2023-07-30 |
Franklin Strategic Series-Franklin Biotechnology Discove |
294.80K |
218.15K |
0.85% |
2023-06-29 |
Vanguard Extended Market Index Fund |
242.41K |
181.81K |
0.70% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
123.50K |
92.63K |
0.36% |
2023-05-30 |
Fidelity Extended Market Index Fund |
88.26K |
54.28K |
0.26% |
2023-05-30 |
Fidelity Total Market Index Fund |
21.68K |
13.33K |
0.06% |